Shire, an Irish drug company with about 1,400 employees in Lexington, said Friday it has received US regulatory approval to make the Gaucher disease drug Vpriv at its manufacturing facility there.
The facility was previously approved by European regulators for the production of Vpriv. Gaucher disease is a rare genetic disorder.
Shire PLC said it has invested more than $200 million in manufacturing infrastructure and technology to establish a consistent drug supply chain to patients.
The company also has a facility in the Alewife neighborhood of Cambridge.
Vpriv has been approved in more than 40 countries.